Literature DB >> 18836470

How tumours escape mass destruction.

T J Stewart1, S I Abrams.   

Abstract

It is now well established that the immune system can control neoplastic development and growth in a process termed immunosurveillance. A link between host immunosurveillance and neoplastic progression is revealed in cases where the immune response becomes compromised due to genetic or other pathological conditions, resulting in a substantially increased incidence and rate of spontaneous tumour formation in both preclinical animal models and patients. It has also been demonstrated in tumour-bearing hosts that the tumorigenic process itself can promote a state of immunosuppression that, in turn, facilitates neoplastic progression. The ability of neoplastic populations to induce a hostile microenvironment through both cell contact-dependent and -independent immunosuppressive networks is a significant barrier to effective cell-mediated immunity and immunotherapy. Thus, a competent immune system is integral for the control of neoplastic disease, and dissecting the plethora of tumour escape mechanisms that disrupt this essential host defense capability is integral for the development of effective immunotherapeutic paradigms.

Entities:  

Mesh:

Year:  2008        PMID: 18836470     DOI: 10.1038/onc.2008.268

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  75 in total

Review 1.  Designing T cells for cancer immunotherapy.

Authors:  Leslie E Huye; Gianpietro Dotti
Journal:  Discov Med       Date:  2010-04       Impact factor: 2.970

Review 2.  Genetic modification of T cells.

Authors:  Chiara Bonini; Malcolm K Brenner; Helen E Heslop; Richard A Morgan
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

3.  Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells.

Authors:  Melissa G Lechner; Daniel J Liebertz; Alan L Epstein
Journal:  J Immunol       Date:  2010-07-19       Impact factor: 5.422

Review 4.  Adoptive T cell therapy of cancer.

Authors:  Malcolm K Brenner; Helen E Heslop
Journal:  Curr Opin Immunol       Date:  2010-02-17       Impact factor: 7.486

5.  Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis.

Authors:  Yingjie Wu; Pnina Brodt; Hui Sun; Wilson Mejia; Ruslan Novosyadlyy; Nomeli Nunez; Xiaoli Chen; Arnulfo Mendoza; Sung-Hyeok Hong; Chand Khanna; Shoshana Yakar
Journal:  Cancer Res       Date:  2010-01-01       Impact factor: 12.701

6.  BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.

Authors:  Trevor E Angell; Melissa G Lechner; Julie K Jang; Adrian J Correa; Jonathan S LoPresti; Alan L Epstein
Journal:  Thyroid       Date:  2014-07-15       Impact factor: 6.568

7.  A novel combination strategy for effectively targeting cancer stem-like cells.

Authors:  Paul A Beavis; Emma V Petley; Phillip K Darcy
Journal:  Immunol Cell Biol       Date:  2017-06-06       Impact factor: 5.126

Review 8.  Stem cell replication, somatic mutations and role of randomness in the development of cancer.

Authors:  Vittorio Perduca; Ludmil B Alexandrov; Michelle Kelly-Irving; Cyrille Delpierre; Hanane Omichessan; Mark P Little; Paolo Vineis; Gianluca Severi
Journal:  Eur J Epidemiol       Date:  2019-01-08       Impact factor: 8.082

9.  On statistical modeling of sequencing noise in high depth data to assess tumor evolution.

Authors:  Raul Rabadan; Gyan Bhanot; Sonia Marsilio; Nicholas Chiorazzi; Laura Pasqualucci; Hossein Khiabanian
Journal:  J Stat Phys       Date:  2017-12-21       Impact factor: 1.548

10.  Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.

Authors:  Rebecca L Vartuli; Hengbo Zhou; Lingdi Zhang; Rani K Powers; Jared Klarquist; Pratyaydipta Rudra; Melanie Y Vincent; Debashis Ghosh; James C Costello; Ross M Kedl; Jill E Slansky; Rui Zhao; Heide L Ford
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.